APTORUM GROUP LTD-CLASS A (APM) Stock Price, Quote, News and Overview
NASDAQ:APM - Nasdaq - KYG6096M1226 - Common Stock - Currency: USD
APM Quote, Performance and Key Statistics
APTORUM GROUP LTD-CLASS A
NASDAQ:APM (2/5/2025, 8:00:00 PM)
After market: 1.17 +0.01 (+0.86%)1.16
-0.04 (-3.33%)
The current stock price of APM is 1.16 USD. In the past month the price decreased by -27.95%. In the past year, price decreased by -20.55%.
APM Latest News, Press Releases and Analysis
Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering
Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) (
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
APM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.95 | 338.85B | ||
| AMGN | AMGEN INC | 15.53 | 165.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 957.73 | 125.79B | ||
| GILD | GILEAD SCIENCES INC | 22.49 | 124.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.7 | 78.76B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.64B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.34B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.26B | ||
| NTRA | NATERA INC | N/A | 23.37B | ||
| BIIB | BIOGEN INC | 8.91 | 21.21B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.55 | 15.81B |
Related stock screener links
About APM
Company Profile
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.
Company Info
APTORUM GROUP LTD-CLASS A
17 Hanover Square
London W1S 1BN GB
CEO: Ian Huen
Employees: 3
Company Website: http://www.aptorumgroup.com/
Investor Relations: http://ir.aptorumgroup.com
Phone: 442080929299
APM FAQ
What is the stock price of APM?
The current stock price of APM is 1.16 USD.
What is the symbol for APTORUM GROUP LTD-CLASS A stock?
The exchange symbol of APTORUM GROUP LTD-CLASS A is APM and it is listed on the Nasdaq exchange.
On which exchange is APM stock listed?
APM stock is listed on the Nasdaq exchange.
Is APM a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for APM, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of APM.
Does APM stock pay dividends?
APM does not pay a dividend.
What is the Price/Earnings (PE) ratio of APM?
The PE ratio for APM is 58. This is based on the reported non-GAAP earnings per share of 0.02 and the current share price of 1.16 USD.
What is the Short Interest ratio of APM stock?
The outstanding short interest for APM is 2.71% of its float.
APM Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to APM. When comparing the yearly performance of all stocks, APM is a bad performer in the overall market: 81.76% of all stocks are doing better.
APM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APM. APM may be in some trouble as it scores bad on both profitability and health.
APM Financial Highlights
Over the last trailing twelve months APM reported a non-GAAP Earnings per Share(EPS) of 0.02. The EPS decreased by 100.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 0.11% | ||
| ROE | 0.08% | ||
| Debt/Equity | 0.14 |
APM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to APM. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 86.79% and a revenue growth 9197.28% for APM